Lilly to Build $3B Manufacturing Facility in Netherlands
Eli Lilly and Company is investing $3 billion to build a new manufacturing facility in Katwijk, the Netherlands, within the Leiden Bio Science Park....
Lilly, NVIDIA Partner on AI Supercomputer for Drug Research
Eli Lilly and Company has revealed plans to construct what it calls the most powerful supercomputer ever built and operated by a pharmaceutical company,...
FDA Unveils Initiative for Faster Biosimilar Development
The U.S. Food and Drug Administration (FDA) has unveiled a major initiative aimed at cutting both the time and cost required to develop biosimilar...
AstraZeneca Secures EU Approval for Koselugo to Treat NF1 PN
Alexion, an AstraZeneca rare disease, has received EU approval for Koselugo (selumetinib), its oral, selective MEK inhibitor, to treat symptomatic, inoperable plexiform neurofibromas (PN)...
Guardant Health, Zephyr AI Collab to Advance Cancer Research
Guardant Health and Zephyr AI have formed a strategic partnership to push forward the discovery of new cancer biomarkers and strengthen precision oncology efforts....
FDA Approves Omvoh by Eli Lilly for Ulcerative Colitis
Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved a new single-injection, once-monthly maintenance option (200 mg/2...
Novartis to Acquire Avidity Biosciences in $12 Billion Deal
Swiss pharmaceutical company Novartis announced that it has reached an agreement to acquire U.S.-based biotechnology firm Avidity Biosciences in a cash deal valued at...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...